These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2073666)

  • 1. HMG CoA reductase inhibitors: new horizons in the management of hypercholesteremia. XIth Congress of the European Society of Cardiology. Nice, France, September 10-14, 1989.
    Cardiology; 1990; 77 Suppl 4():1-69. PubMed ID: 2073666
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New drugs for treating hypercholesterolemia and other hyperlipidaemias--the HMG CoA reductase inhibitors.
    Berger GM; Marais AD; Firth JC
    S Afr Med J; 1990 Jan; 77(2):57-9. PubMed ID: 2404345
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust.
    Davidson MH
    Drugs; 2001; 61(2):197-206. PubMed ID: 11270938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia.
    Grundy SM
    N Engl J Med; 1988 Jul; 319(1):24-33. PubMed ID: 3288867
    [No Abstract]   [Full Text] [Related]  

  • 6. [HMG-CoA reductase inhibitors: anti-atherosclerotic effects other than lipid-lowering].
    Fujita R; Matsushima T
    Nihon Rinsho; 1999 Dec; 57(12):2821-5. PubMed ID: 10638219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HMG-CoA reductase inhibitors for hypercholesterolemia.
    N Engl J Med; 1988 Nov; 319(18):1222-3. PubMed ID: 3173461
    [No Abstract]   [Full Text] [Related]  

  • 8. [New perspectives in the control of hypercholesterolemia with the use of HMG CoA reductase inhibitors].
    Ribeiro L; Kohn IJ
    Arq Bras Cardiol; 1990 Mar; 54(3):177-8. PubMed ID: 2288502
    [No Abstract]   [Full Text] [Related]  

  • 9. HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre.
    de Langen JJ; van Puijenbroek EP
    Neth J Med; 2006 Oct; 64(9):334-8. PubMed ID: 17057271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atorvastatin calcium: an addition to HMG-CoA reductase inhibitors.
    Chong PH; Seeger JD
    Pharmacotherapy; 1997; 17(6):1157-77. PubMed ID: 9399600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HMG-CoA reductase inhibitory activity and phytocomponent investigation of Basella alba leaf extract as a treatment for hypercholesterolemia.
    Baskaran G; Salvamani S; Ahmad SA; Shaharuddin NA; Pattiram PD; Shukor MY
    Drug Des Devel Ther; 2015; 9():509-17. PubMed ID: 25609924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of childhood hypercholesterolemia with HMG-CoA reductase inhibitors.
    Duplaga BA
    Ann Pharmacother; 1999 Nov; 33(11):1224-7. PubMed ID: 10573325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacological effects of HMG-CoA reductase inhibitors].
    Tomita N; Morishita R; Ogihara T
    Nihon Rinsho; 2002 May; 60(5):955-61. PubMed ID: 12029999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [What is assured in therapy with HMG-CoA reductase inhibitors (cholesterol synthesis inhibitors)?].
    Knisel W; Eggstein M
    Internist (Berl); 1989 Dec; 30(12):776-83. PubMed ID: 2695487
    [No Abstract]   [Full Text] [Related]  

  • 15. HMG-CoA reductase inhibition: the start of a new age in the treatment of hypercholesterolaemia.
    Meinders AE
    Neth J Med; 1988 Jun; 32(5-6):213-6. PubMed ID: 3292961
    [No Abstract]   [Full Text] [Related]  

  • 16. Advances in treatment of cholesterol abnormalities. The role of HMG-CoA reductase inhibitors.
    Rackley CE
    Postgrad Med; 1996 Nov; 100(5):61-5, 70-2. PubMed ID: 8917325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of virtual screening, flexible docking, and molecular interaction fields to design novel HMG-CoA reductase inhibitors for the treatment of hypercholesterolemia.
    da Silva VB; Taft CA; Silva CH
    J Phys Chem A; 2008 Mar; 112(10):2007-11. PubMed ID: 18044855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
    Hilleman DE; Phillips JO; Mohiuddin SM; Ryschon KL; Pedersen CA
    Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic aspects of hypercholesterolemia treatment with HMG-CoA reductase inhibitors: a review of recent developments.
    MacNeil P
    Can J Cardiol; 1998 Apr; 14 Suppl A():14A-16A. PubMed ID: 9594928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [HMG-CoA-reductase inhibitors: a new principle in the treatment of hypercholesterolemia].
    Saxenhofer H; Weidmann P
    Ther Umsch; 1990 Jun; 47(6):509-13. PubMed ID: 2375007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.